Iovance Biotherapeutics, Inc. Stock News

SAN CARLOS, Calif., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou

Iovance is ramping up tumor-infiltrating lymphocytes as an ingenious way to eradicate cancers. As such, I believe it'll continue to deliver stellar data. Riding robust data, LPN-145 and lifileucel, ar

SAN CARLOS, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou

SAN CARLOS, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou

SAN CARLOS, Calif., Nov. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou

44.4% Overall Response Rate (ORR) and Median Duration of Response (DOR) Not Reached at 8.6 Months of Study Follow Up

Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q3 2020 Results - Earnings Call Transcript

SAN CARLOS, Calif., Oct. 30, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, will report

SAN CARLOS, Calif., Oct. 28, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou

Iovance Biotherapeutics, in an attempt to secure FDA-approval for their biologic, lifileucel, in advanced melanoma, was set back as the FDA requires some more information. This can't come to much of a

That fewer Americans smoke tobacco has led to a significant decline in lung cancer deaths. Advances in treatment are also a major contributor.

Iovance's (IOVA) second-quarter bottom line beats estimates. The company is progressing well with its lead pipeline candidates.

Seneca Biopharma (NASDAQ:SNCA) and Iovance Biotherapeutics (NASDAQ:IOVA) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of th

SAN CARLOS, Calif., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today annou

Enrollment Completed in Pivotal Cohort 1 of C-145-04 Cervical Cancer StudySAN CARLOS, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology